Atossa Therapeutics Q2 net loss widens on lower interest income

Atossa Therapeutics

07/08/2026 14:02

Overview
US biopharmaceutical developer reported slightly bigger Q2 net loss of $8.5 mln, but narrower loss per share of $0.95
Company's operating expenses fell slightly as preclinical trials ended but interest income dropped due to lower average investment
Atossa raised $4.5 mln in upfront proceeds via registered direct offering, with potential for more

Outlook
Company did not provide specific financial guidance for the current or future periods

Result Drivers
R&D costs drop - Co said lower Q2 R&D professional fees were mainly due to completion of preclinical trials for (Z)-endoxifen, though R&D compensation rose
CLINICAL TRIAL ENROLLMENT - Co reported increased clinical trial expenses due to higher enrollment and drug development costs for (Z)-endoxifen
LEGAL FEES - Co said higher general and administrative expenses were due to increased legal fees related to patent litigation and compliance

Company press release: ID:nPn6ZCVkra

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.95
 
Q2 Operating Income
 
-$8.70 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Atossa Therapeutics Inc is $22.00, about 809.1% above its August 6 closing price of $2.42

Reuters Recommended Reads
Aug 6 - Janux Therapeutics Q2 net loss narrows as expenses fall
Aug 6 - Biopharma firm IN8bio's Q2 net loss narrows as expenses decline
Aug 6 - Cognition Therapeutics Q2 net loss narrows on lower R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)